ArticleScientific reports2021

Systemic immunity markers associated with lymphocytes predict the survival benefit from paclitaxel plus bevacizumab in HER2 negative advanced breast cancer.

Shogo Nakamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.